Human APRIL Antibody - Sibeprenlimab Biosimilar

Human IgG2 - CAS #2382896-07-1

ABOUT

Anti-human APRIL - Sibeprenlimab biosimilar - CAS #2382896-07-1

Anti-hAPRIL-hIgG2 is a biosimilar antibody of Sibeprenlimab, a human APRIL (A proliferation-inducing ligand) antibody that blocks APRIL signaling. This monoclonal antibody (mAb) has progressed to phase 2/3 clinical trials to treat patients with immunoglobulin A nephropathy (IgAN).

More details More details 


Anti-hAPRIL-hIgG2 comprises the variable region of Sibeprenlimab and the IgG2 constant region of Sibeprenlimab, mediating mild effector functions. 

This antibody can be used together with HEK-Blue™ BCMA cells for screening and neutralization assays to block BAFF/BCMA signaling induced by recombinant human APRIL (see figure).

 

Key features

  • Each lot is functionally tested and validated.
  • The complete sequence of the antibody construct was verified.
  • The absence of endotoxins is determined by the EndotoxDetect™ assay.

All InvivoGen products are for research use only and are not intended for human or veterinary use.

Binding of Anti-APRIL Sibeprenlimab
Binding of Anti-APRIL Sibeprenlimab

SPECIFICATIONS

Specifications

Target

APRIL

Target species

Human

Applications

Neutralization assay (tested), ELISA

Species
Human
Isotype
hIgG2
kappa
Recommended isotype control
Human IgG2 Isotype Control Antibody
Clone
Sibeprenlimab
CAS number
2382896-07-1
Synonyms
VIS649
VIS-649
Molecular weight
150 kDa
Tag
Tag-free
Source
CHO cells
Production details
Animal-free
Purification
Protein A
Formulation buffer

Sodium phosphate buffer with glycine, saccharose, and stabilizing agents

Preservative
Azide-free
Purity
≥ 95 %
Appearance (form)
Lyophilized
Reconstitution buffer
Sterile water (not provided)
Sterility

0.2 µm filtration

Endotoxin

Negative (tested using EndotoxDetect™ assay)

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Anti-hAPRIL-hIgG2
  • Cat code: 
    hapril-mab2
  • Quantity: 
    100 µg

Shipping & Storage

  • Shipping method:  Room temperature

    • Storage:

    • -20°C
    Stability: -20°C for up to 1 year

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

Sibeprelimab background

Sibeprenlimab (aka VIS-949) is a therapeutic, humanized monoclonal antibody (mAb) that targets the human APRIL (A proliferation-inducing ligand) [1]. By binding to APRIL, Sibeprenlimab prevents it from interacting with its receptors TACI and BCMA on the surface of immune cells, thus inhibiting its downstream functions, notably mature B cell development, immunoglobulin (Ig) class switching, and plasmocyte survival [1].
APRIL is a member of the tumor necrosis factor cytokine family [2]. Together with the related cytokine BAFF (B-cell activation factor), it belongs to the BAFF-APRIL system, which is critical for B-cell function. Dysregulation in the BAFF-APRIL axis is associated with autoimmune diseases, including systemic lupus erythematosus (SLE)3 and immunoglobulin A nephropathy (IgAN)[1,2], as well as blood cancers [3].
Sibeprenlimab has been under clinical evaluation for the treatment of immunoglobulin A nephropathy (IgAN) [4,5].

 

References:

1. Myette J.R., et al., 2019. A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy. Kidney International. 96(1):104.
2. Mathur M., et al., 2022. Safety, tolerability, pharmacokinetics, and pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers. Kidney International Reports. 7(5):993.
3. Ullah M.A. & Mackay F., 2023. The BAFF/APRIL system in cancer. Cancers. 15:1791.
4. NCT05248646 https://clinicaltrials.gov (accessed October 2025). 
5. NCT05248659 https://clinicaltrials.gov (accessed October 2025). 

You may also need

Citations

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?